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ABSTRACT 
 
DOPPLER PARAMETERS OF HEPATIC HEMODYNAMICS IN 
CIRRHOTICS - ITS CLINICAL AND HISTOLOGICAL 
CORRELATION 
 
AIM OF THE STUDY 
To compare the Doppler parameters such as Hepatic artery Pulsatile and 
Resistive indices of compensated and decompensated cirrhotics. 
To correlate these doppler parameters with clinical, biochemical and 
histological parameters in compensated cirrhotics and to carry out clinical and 
biochemical correlation in decompensated cirrhotics. 
INTRODUCTION 
 
Cirrhosis is a diffuse process characterised by fibrosis and conversion of 
normal liver into abnormal nodules8.Cirrhosis is most common cause of Portal 
Hypertension (PHT).Cirrhosis characterised by alteration in systemic and 
splanchnic hemodynamics1,2,3. Alteration of these hemodynamics leads to Portal 
Hypertension. There are various methods to assess portal hypertension. Liver 
biopsy is the gold standard for diagnosis of liver fibrosis.  
MATERIALS AND METHODS 
The study was carried during the period June 2013- February 2014. 20 
cases each of Compensated and Decompensated cirrhosis were involved in the 
study. 
  
RESULTS 
Variable COMPENSATED DECOMPENSATED P value 
HAPI 1.76 1.92 < 0.001 
HARI 0.69 0.87 < 0.001 
MELD 9.5 13.8 < 0.001 
 
CONCLUSION   
1. HAPI is indicator of severity of resistance due to fibrosis in both study 
groups. 
2. HAPI and HARI similar to that of MELD are non invasive doppler 
parameters predicting severity of liver disease and its progression. 
3. Hepatic artery pulsatile index had significant correlation with AST, 
indicating severe fibrosis and severe form of liver disease. 
4. All patients in compensated group had cirrhosis (F4) hence 
histological correlation could not be carried out. 
                                                                                              1 
 
INTRODUCTION 
Cirrhosis is a diffuse process characterised by fibrosis and conversion of 
normal liver into abnormal nodules8.Cirrhosis is most common cause of Portal 
Hypertension (PHT).Cirrhosis characterised by alteration in systemic and 
splanchnic hemodynamics1,2,3. Alteration of these hemodynamics leads to Portal 
Hypertension. There are various methods to assess portal hypertension. Liver 
biopsy is the gold standard for diagnosis of liver fibrosis. Non invasive methods 
for assessment of PHT include Doppler Ultrasonography, hepatic vein pressure 
gradient, splenic pulp pressure and endoscopic variceal pressure. 
Doppler Ultrasonography is inexpensive and non-invasive tool to assess 
focal and diffuse parenchymal changes in liver4. Investigators documented increase 
in renal resistance in cirrhotics5,6 . Doppler parameters correlate with complications 
of portal hypertension. These doppler parameters used for assessment of prognosis 
and response to pharmacological treatment. 
Hepatic artery and Renal artery Resistive index (HARI) and Pulsatile index 
(HAPI) were studied by Rivolta et al5. Higher the Hepatic artery Resistive indices, 
more is the severity of ascites and complications. Resistive index of hepatic artery 
is inversely related to organ perfusion. 
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Gaiani et al. (11) noted that spontaneous hepatic encephalopathy more 
frequent in patients with hepatofugal flow in the portal system (21% vs. 7.2%; P < 
0.05).  
Sacerdoti et al7 showed that higher the RI in intrarenal arteries predicts 
development of Hepatorenal syndrome and poor survival. Advantages of Doppler 
are safe, inexpensive and painless. Disadvantages it is operator dependent. 
Limitations of doppler are obesity, excess bowel gas and respiratory movement. 
Cirrhosis associated with increased intrahepatic resistance. It leads to 
increased resistance in main portal vein. Wachsberg et al. (9) pointed out that the 
prevalence of hepatofugal flow varied between 3% and 23%. Child and Turcotte 
first introduced their scoring system in 1964 which was subsequently revised by 
Pugh in 1973(10). Child Turcotte Pugh (CTP) score is widely used for prognosis 
and for clinical correlation. 
    There are few studies correlating Doppler parameters with clinical, 
biochemical and histological parameters. This study is carried to validate the 
correlation and to assess the outcome. 
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AIM OF THE STUDY 
1. To compare the Doppler parameters such as Hepatic artery Pulsatile and 
Resistive indices of compensated and decompensated cirrhotics. 
 
2. To correlate these doppler parameters with clinical, biochemical and 
histological parameters in compensated cirrhotics and to carry out clinical 
and biochemical correlation in decompensated cirrhotics. 
 
 
 
 
 
 
 
 
 
 
                                                                                              4 
 
REVIEW OF LITERATURE 
LIVER FIBROSIS 
Liver fibrosis is accumulation of extracellular matrix proteins (ECM) in 
chronic liver diseases12.  Most common causes of liver fibrosis are Chronic Viral 
Hepatitis, Alcohol abuse and Non alcoholic steatohepatitis. Accumulation of ECM 
proteins leads to scar and nodule formation leads to cirrhosis. Cirrhosis leads to 
increased intrahepatic resistance, hepatic insufficiency and portal hypertension. 
     Most important cell involved in Hepatic fibrosis is Hepatic stellate cell 
(HSC) or “Ito cell”. Normally it is involved with vitamin A storage14. First 
described by Von Kuppfer in 1876. Onset of fibrosis is insidious progresses to 
cirrhosis in 15-20 yrs. 
Liver fibrosis is influenced by genetic and environmental factors. Chronic 
Viral hepatitis and Alcohol account for half of cases1. 
  Major clinical complications of cirrhosis include ascites, renal failure, 
hepatic encephalopathy, and variceal bleeding. Patients with compensated cirrhosis 
remain free of complications compared to decompensated cirrhotics. 
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Properties of activated stellate cell 
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CAUSES OF LIVER FIBROSIS 
Chronic viral diseases                            Autoimmune diseases 
Hepatitis B                                               Autoimmune hepatitis 
Hepatitis C                                               Primary Biliary Cirrhosis 
Hepatitis D                                               Primary sclerosing cholangitis 
                                                                  Graft versus host disease 
Drugs                                                        Metabolic causes 
Methotrexate                                             Nonalcoholic steatohepatitis 
α methyl dopa                                            Wilsons disease 
Amiodarone                                               Hemochromatosis 
Vitamin A intoxication                              α1 Antitrypsin deficiency 
                                                                    Type 4 Glycogen storage disease 
                                                                    Tyrosinemia 
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Vascular 
Budd chiari syndrome 
Venoocclusive disease 
 IVC thrombosis 
 Rt.sided Heart failure. 
 
Miscellaneous 
Secondary biliary cirrhosis 
Cryptogenic 
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Cellular mechanisms of liver fibrosis 
HSC activation is the key step in hepatic fibrogenesis. These cells contribute 15% 
of liver population. Hepatocytes and Kuppfer cells promote HSC activation by 
lipid peroxides leads to oxidative stress. Antioxidants attenuate liver fibrogenesis 
by inhibiting these cells. Most important growth factor involved is PDGF. 
 
  Interaction of HSC with extracellular matrix important in profibrogenic behavior. 
These cells play active role in hepatic inflammation15. Myofibroblasts are other 
cells known to have fibrogenic potential. 
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Sources of Myofibroblasts 
Various sources of Myofibroblasts are Hepatocyte, Cholangiocyte, portal 
fibroblast, Quiescent HSC. 
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MOLECULAR MECHANISMS IN LIVER FIBROSIS 
Liver fibrosis is due to alteration and change of composition of Extracellular 
matrix proteins16. Major extracellular matrix component in fibrotic liver is Type 1 
collagen. Mechanisms of liver fibrosis include oxidative stress, hypoxia and 
angiogenesis. Oxidative stress play major role in hepatic fibrogenesis. NADPH 
complex plays novel regulator in liver fibrogenesis. 
Several cytokines regulate liver fibrogenesis. TGF-β is most effective 
fibrogenic cytokine in liver. Several growth factors such as PDGF, EGF and IGF 
play an important role of which Platelet derived growth factor (PDGF) is most 
important. 
        Angiotensin2 plays important role in hepatic fibrogenesis17. 
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PATHOGENIC EFFECT OF RENIN ANGIOTENSIN SYSTEM 
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PATHOGENESIS OF LIVER FIBROSIS 
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GENETIC DETERMINANTS OF LIVER FIBROSIS 
Liver fibrosis is a condition in which multiple genes interact with 
environmental factors18. .Alcoholic liver disease characterized by interaction by 
genetic, environmental and behavioral factors. Studies have identified 
polymorphisms in a number of candidate genes that may influence the progression 
of liver fibrosis in humans19.. 
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PORTAL HYPERTENSION (PHT) 
 
 
It is a pathologic increase in hydrostatic pressure in the portal venous 
system. Ninety percent of patients with PHT have sinusoidal or post sinusoidal 
portal hypertension. It is caused mainly by cirrhosis due to Hepatitis B or C 
infection. 
      Cirrhosis characterised by fibrosis and formation of nodules. Formation of 
nodules leads to distortion of hepatocyte architecture and leads to portal 
hypertension. Normal portal pressure is 5- 10 mmHg. Normal Portal vein (PV) 
flow is Hepatopetal and usually monophasic with some fluctuation due to 
respiration and cardiac activity. Normal Portal vein diameter is 13 mm.  
Dilatation of portal vein is when more than 13mm occurs in 56% of pts. 
Normal caliber of  PV does not however exclude PHT. Upper limit of normal 
splenic and superior mesenteric vein are 10-12 mm. Splenomegaly usually 
associated with dilatation of Splenic vein. PHT  is measured by several methods: 
1. Doppler ultrasonography 
2. Hepatic vein pressure gradient 
3. Splenic pulp pressure 
4. Portal vein pressure 
5. Endoscopic variceal pressure 
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Hepatic vein pressure gradient (HVPG) is wedge hepatic pressure- free 
hepatic vein pressure. First described in 1951. 
Indications for measurement of  HVPG 
1. To monitor portal pressure 
2. Prognostic marker 
3. Assess risk of hepatic resection in patients with cirrhosis 
4. Delineate cause of portal hypertension 
5. Endpoint in trials using drugs for portal hypertension 
DOPPLER FINDINGS IN PHT 
1. Dilated splenoportal axis 
2. Portosytemic collaterals 
3. Hepatofugal flow 
4. Phasic variation of Hepatic vein reduced or absent 
5. SMA shows decrease pulsatility index. 
       In cirrhosis the portal vein blood flow is reduced. It is compensated by 
hepatic arterial flow. In setting of cirrhosis measurement of Hepatic arterial 
Pulsatile index and Resistive indices are markers of resistance. Hence 
measurement of these parameters is more valid than measurement of routine 
doppler parameters. 
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PULSATILITY AND RESISTIVE INDICES 
Hepatic artery resistance can be measured by measuring the Resistive index 
(RI) and Pulsatile index (PI). Although these indices are closely correlated, hepatic 
artery Pulsatile index is considered a better index of resistance. Since these indices 
are ratios which can be measured by calculating the peak systolic velocity, peak 
diastolic velocity and mean velocity they are less likely to be affected by subjective 
measurements. 
      Hepatic arterial resistive indices have been shown to increase in cirrhosis 
and portal hypertension. Schneider et al [43] reported that hepatic arterial 
Pulsatile index is higher in cirrhotics compared to controls in his study and found 
direct correlation with portal pressure. Hepatic arterial pulsatility index correlated 
with non-invasive assessment of portal hypertension. 
      The pathological mechanisms resulting in PHT are narrowing of vascular 
space by fibrous tissue, compression by regenerative nodules, increased 
contractility in response to vasoconstrictors. 
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OTHER DOPPLER INDICES IN VARIOUS STUDIES 
1. Portal vein congestive index (PVCI) is defined as ratio of cross sectional 
area of the extra-hepatic portal vein to time averaged mean velocity of blood 
flow in the portal vein. Elevated in cirrhotics. 
2.  Doppler perfusion index (DPI) is the ratio of hepatic arterial blood flow 
(normal below 20 %) to the total liver blood flow (hepatic arterial and portal 
venous blood flow). Elevated in Cirrhotics. 
Doppler Perfusion Index(DPI)  = Blood flow of hepatic artery 
(Blood flow of hepatic artery + blood flow of portal vein) 
                   DPI= BFHA / (BFHA+BFPV) 
Gaiani et al [20] showed that 80.4% of cirrhosis can be detected in patients 
with compensated liver diseases of various etiologies using a US scoring system 
based on two US parameters..   
Colli et al [21] reported that US can detect severe fibrosis or cirrhosis with a 
specificity of 0.95 and a sensitivity of only 0.54. 
Zheng et al [22] studied value of US in evaluation of liver fibrosis and 
compensated cirrhosis in comparison with serology and histology, found that 
hepatic parenchymal echo pattern, liver surface and thickness of gallbladder wall 
are three independent predictors of liver fibrosis. 
Diagnostic accuracy of USG for compensated cirrhosis is 80.5%. 
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Doppler USG measurement does not represent HVPG. 
Schalm et al [ 23] showed that even if histology shows no evidence of 
cirrhosis but if there is fibrosis and architectural distortion, diagnosis of cirrhosis 
should be made if there is ultrasound evidence of cirrhosis. 
Hemodynamics in hepatic blood flow influenced by extent of fibrosis, 
chronic inflammation, presence and size of varices and portosystemic shunts. 
Other noninvasive method of assessing liver fibrosis is Transcient elastography. 
TRANSCIENT ELASTOGRAPHY (FIBROSCAN) 
Mild amplitude and low frequency wave is transmitted to tissue producing 
shear wave within liver. It is noninvasive useful in several liver diseases. 
Limitations not used in morbid obesity. Liver stiffness always is not a surrogate 
marker of fibrosis. Useful in mild and advanced fibrosis not useful in intermediate 
fibrosis. 
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NON INVASIVE ASSESSMENT OF FIBROSIS 
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Hepatic artery Pulsatile index (HAPI) and Resistive indices (HARI) 
calculated using following formulas: 
 
HEPATIC ARTERY  
RESISTIVE INDEX (RI) = Peak Systolic velocity -- Peak Diastolic velocity 
                                                              Peak systolic velocity 
 
HEPATIC ARTERY 
PULSATILE INDEX (PI) = Peak Systolic velocity -- Peak Diastolic velocity 
                                                                      Mean velocity 
 
Hepatic artery Pulsatile and Resistive indices were studied by assessing 
blood flow velocity waveform analysis by doppler studies. 
 
Hyperdynamic circulation in splanchnic and systemic areas seen in advanced 
liver diseases. Schrier et al suggested that these hemodynamic changes can be 
seen in early stages of cirrhosis. 
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Portal Doppler was done. In it various parameters such as assessment of 
portal vein size, liver echoes, presence of splenomegaly, and presence of 
collaterals were assessed. Normal individual’s diameter of portal vein should not 
exceed 13 mm in supine posture and quiet respiration. 
 
       PHT defined when size of PV more than 13mm. It has high specificity of 
100% and sensitivity of 45- 50% 26, 27. In normal individuals the diameter of portal 
vein increases by 70 -100% from quiet respiration to deep inspiration. 
 
     In normal individuals flow is Hepatopetal throughout entire cardiac cycle. Flow 
velocity is about 15- 18 cm/sec. The following changes seen with portal 
hypertension: 
 
1. Flow becomes continuous 
2. Bidirectional 
3. Hepatofugal 
4. Development of collaterals 
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Cirrhosis is characterized by increased intrahepatic resistance. This leads to 
resistance to hepatopetal flow in main portal vein. This leads to opening of 
collaterals. 
 
                                              HEPATOPETAL FLOW 
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With progressive intrahepatic resistance leads to reversal of flow in main 
portal vein leads to hepatofugal flow. Wachsberg et al [28] reported prevalence of 
Hepatofugal flow in 3- 23% in his studies. 
 
                                    HEPATOFUGAL FLOW 
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Taourel et al [29] reported no correlation between degree of PHT and 
development of esophageal varices. Ohnishi et al [30] reported decreased portal 
velocity and hepatofugal flow associated with development of splenic varices. 
Gaiani et al [31] reported spontaneous hepatic encephalopathy incidence high in 
patients with Hepatofugal flow. 
SPLENIC VARICES 
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LIVER BIOPSY 
Liver biopsy is the gold standard for diagnosis of liver fibrosis. The tissue 
obtained represents 1/ 50,000 th of liver tissue. Ideal biopsy sample should contain 
at least 11 portal tracts. There are several methods of liver biopsy 
1. Percutaneous route 
2. Transjugular route 
3. Transthoracic route 
   Role of liver biopsy: 
1. For diagnosis 
2. For assessment of prognosis 
3. For assisting in management of therapeutic decisions. 
 INDICATIONS   
1. Unexplained elevation of liver enzymes. 
2. Elevated liver enzymes for 6 months or longer. 
3. Assessment of response to therapy of chronic liver disease 
4. Multiple parenchymal liver diseases. 
5. Fever of unknown origin. 
6. Focal or diffuse abnormalities on imaging. 
7. Staging / Prognosis of liver diseases. 
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PREBIOPSY WORK UP 
1. Prothrombin time/ INR and partial thromboplastin time should be assessed. 
2. Platelet count 
3. Hemoglobin 
4. Blood urea nitrogen and creatinine 
5. Bleeding time 
6. Antiplatelet/ warfarin / heparin to be stopped. 
 
CONTRAINDICATIONS 
1. Uncooperative patient. 
2. Impaired coagulation 
3. Severe uncorrected anemia 
4. Significant ascites 
5. Skin infection at needle insertion site. 
6. High grade extrahepatic Biliary obstruction 
7. Cholangitis / Uremia 
8. Leukemia/  Myelofibrosis 
9. Echinococcal cysts 
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BIOPSYGUN
 
COMPLICATIONS 
1. Pain is the most common complication seen in 3-33% pts 
2. Bleeding 
3. Hypotension 
4. Hemothorax 
5. Hemoperitoneum 
6. Hematoma 
7. Hemobilia 
8. Gall bladder perforation 
 
Most complications occur within 2hrs. Patient to be monitored every 15 
minutes for 1hr, thereafter every 30 minutes for 2 hours. 
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FIBROSIS SCORING SYSTEMS 
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METAVIR AND LUDWIG SCORES 
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Comparison of Fibrosis Scores 
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MATERIALS AND METHODS 
This is a cross sectional study which was done in Department of Medical 
Gastroenterology in Rajiv Gandhi Government General Hospital Chennai. The 
study was carried during the period June 2013- February 2014. 20 cases each of 
Compensated and Decompensated cirrhosis were involved in the study. 
INCLUSION CRITERIA 
1. Newly diagnosed cases of compensated cirrhosis were selected for study 
based on USG imaging showing nodular appearance of liver, spleen more 
than 12 cm and presence of esophageal varices > 2 on endoscopy based on 
AASLD guidelines. 
2. Cases of Decompensated cirrhosis with ascites, jaundice and encephalopathy 
were selected. 
 
EXCLUSION CRITERIA 
1. Patients with co morbid conditions such Intrinsic Renal disease, Diabetes 
and Hypertension were excluded. 
2. Patients with serum creatinine more than 1.4 mg. 
3.  Patients with malignancy 
 
  
                                                                                              32 
 
DATA COLLECTION 
20 cases of newly diagnosed Compensated cirrhosis and 20 cases of 
Decompensated cirrhosis were selected based on inclusion criteria. Various 
parameters such as age, sex anthropometry were obtained. Clinical features such as 
presence of ascites, jaundice, hepatic encephalopathy, UGI bleed were noted by 
interviewing and thorough examination of the patients. Clinical features suggestive 
of chronic liver disease found during examination were recorded. Biochemical 
parameters such as complete blood count, blood sugar, urea, creatinine, 
electrolytes, liver function tests, prothrombin time were collected.  Imaging such as 
ultrasound abdomen with Doppler study, CT scan, was done as per the 
requirements.  Liver biopsy was done in patients for diagnosis and grading of 
fibrosis. CTP and MELD scores calculated in these patients based on these 
parameters. 
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GRADING OF VARICES 
These pts were subjected to upper gastrointestinal endoscopy for assessment 
of presence or absence of esophageal varices was made. Pacquet classification 
was adopted for grading of esophageal varies. 
 
Pacquet classification  for grading of esophageal varices. 
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PORTAL DOPPLER 
Doppler studies were performed after overnight fasting. Doppler study was 
performed with Duplex Doppler apparatus with color Doppler sonographer and 
3.75 MHz convex transducer is chosen for assessment of deep vessels. The Hepatic 
artery and portal veins best interrogated by Doppler ultrasound of porta hepatis 
using oblique intercostal scans. Parameters such as Hepatic artery Peak systolic 
velocity and Peak diastolic velocity calculated .Using these parameters Hepatic 
artery Pulsatile index (HAPI) and Resistive index (HARI) were calculated as 
follows: 
 
HEPATIC ARTERY  
RESISTIVE INDEX (RI) = Peak Systolic velocity -- Peak Diastolic velocity 
                                                              Peak systolic velocity 
 
HEPATIC ARTERY 
PULSATILE INDEX (PI) = Peak Systolic velocity -- Peak Diastolic velocity 
                                                                      Mean velocity 
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MELD score was calculated in these 2 populations. 
 
MELD is calculated using the following log formula 
    0.957 X loge (creatinine mg/dl) + 0.378 X loge (total bilirubin [mg/dl]) +1.120 
X loge (INR) + 0.643. 
 
Limitations of MELD 
1. Inter laboratory variations measuring creatinine. 
2. Gender differences in creatinine 
3. INR variations. 
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CHILD TURCOTTE PUGH SCORE 
CTP score is calculated based on ascites, hepatic encephalopathy, and 
various other laboratory parameters such as bilirubin, albumin and prothrombin 
time. Various grades such as CTP A, B, and C were given. It is used as a 
prognostic marker. Child Pugh score was assessed.  
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LIVER BIOPSY 
Liver biopsy carried out in cases of compensated cirrhosis after assessment 
of coagulation profile such as prothrombin time, INR, bleeding time and clotting 
time. Platelet count to be assessed. Antiplatelet drugs to be stopped 10 days prior, 
warfarin to be stopped 5 days prior, heparin to be stopped 12-24 hours prior to 
biopsy. 
 
Procedure 
1. Procedure is explained to the patients and consent is obtained. 
2. Test dose of 1% lignocaine is given and tested for anaphylaxis. 
3. Patient is put in reclined posture, head end elevated with arms raised above 
the head. 
4. Maximum point of liver dullness is made out by percussion and is marked. 
Biopsy is done in Rt.9th ICS in midaxillary line. 
5. Area is sterilized on scrubbing with betadine solution.  
6. Patient is explained to hold the breath at end of expiration, so that the liver 
does not move with respiration 
7. 5ml of lignocaine is infiltrated into skin. 
8. Using liver biopsy gun, biopsy is done with “firing” technique. 
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Biopsy specimen fixed in 10% neutral formalin and stained with 
Hematoxylin and eosin or Masson trichrome stains. Ideal biopsy specimen should 
be at least 2 cm in length and not in fragments. It should contain greater than 11 
portal tracts .Liver biopsy to be carried with platelet transfusion when platelet 
count is < 50,000. Patient is observed every 15 minutes for 1 hour and every 30 
minutes for 2 hours. Most common complication seen in our patients was pain at 
biopsy site which was treated with analgesics. 
 
 
SAMPLE LIVER BIOPSY SPECIMEN 
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Statistical analysis 
All the data were entered on a excel sheet. Mean and median were calculated for 
appropriate variables. Variables significant by univariate analysis were again 
compared by multivariate analysis. Pearson correlation coefficient and paired t test 
used for analysis. P value less than 0.05 was taken as significant. P value less than 
0.001 was take to be very statistically significant. Statistical analysis was done by 
SPSS 16 software. 
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RESULTS 
In our cross sectional study a total of 40 pts with chronic liver disease were 
enrolled. Out of which 20 cases each of compensated and decompensated cirrhosis 
were selected. There were 32 males and 8 females. The mean age of presentation 
was 45.5years in compensated group and 48.4 years in decompensated group. Most 
common age group was between 40-50 years which included 16 patients. 
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SEX DISTRIBUTION 
Majority of the study population were males 
 
Figure 1 
Out of 40, history of alcohol consumption present in 30 cases. History of 
upper gastrointestinal bleed present in 28 cases. Encephalopathy present in 9 cases 
seen in decompensated group. Splenomegaly present in 34 cases. Mean 
hemoglobin was 11gm% in compensated and 8.5gm% in decompensated group.  
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Figure 2 
Etiological evaluation done alcohol found to be the common etiological factor 
followed by Hepatitis B viral infection and autoimmune hepatitis. 
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Ascites was present in 20 out of 40 cases. Grading of ascites done as a component 
of Child Pugh score 
 
 
Figure 3 
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Figure 4 
History of UGI bleed present in 28 cases in both groups. The mean hemoglobin 
was low in both groups.   
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Figure 5 
Grading of varices done by Pacquet classification. No varices found in 4 cases. 
Grade 1 varices in 16 cases. Grade 2 in 13 and Grade 3 in 7 cases. 
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Average platelet count in compensated group was 84,600 and 58,700 in 
decompensated group. The albumin level in compensated group was 3.665gm and 
3.25 gm in decompensated. The average bilirubin in compensated was 
1.118 mg% and 7.145 mg% in decompensated group. The prothrombin time in 
compensated was 17.4 and 19.5seconds in decompensated group. AST in 
compensated group was 63 IU and 159 IU in decompensated group. 
 
CTP score was calculated based on presence and severity of ascites, grade of 
encephalopathy, bilirubin, albumin and prolongation of prothrombin time. 
Compensated cirrhosis were in CTP A, whereas decompensated 10 were in CTP B 
and 10 were in CTP C. MELD score was calculated. 18 had MELD score < 10, 22 
had MELD score > 10. 
 
         Various Doppler parameters such as portal vein diameter, phasic variation, 
and direction of flow and presence of collaterals were assessed. Most important 
parameters of resistance such as Hepatic artery Peak systolic flow velocity and 
peak diastolic velocity were calculated. From these values, pulsatile index and 
Resistive indices of Hepatic artery was calculated. 
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Liver biopsy was carried out after prebiopsy workup. Biopsy was done in 
cases of compensated cirrhosis. Using Metavir fibrosis score degree of fibrosis 
calculated. Since study population selected was compensated all cases had F4 
cirrhosis. 
  
          
 
     
 
 
     
 
 
. 
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Table Showing Percentage of Splenomegaly 
 
   
Group 
Total 
Compens
ated 
Decompe
nsated 
Splenomegaly Present Count 17 17 34 
% within 
Splenomegaly 50.0% 50.0% 100.0% 
% within 
Group 85.0% 85.0% 85.0% 
Absent Count 3 3 6 
% within 
Splenomegaly 50.0% 50.0% 100.0% 
% within 
Group 15.0% 15.0% 15.0% 
Total Count 20 20 40 
% within 
Splenomegaly 50.0% 50.0% 100.0% 
% within 
Group 100.0% 100.0% 100.0% 
 
Table shows presence of Splenomegaly in 34 cases and its absence in 6 cases.  
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Table Showing Comparison of HA-PI with AST in both groups 
 
GROUP HAPI AST( IU)  
P value 
< 0.05 
COMPENSATED 1.75 63 
DECOMPENSATED 1.92 159 
 
The above table shows comparison of HAPI with AST. The mean AST in 
compensated group is 63 and 159 in decompensated group.HAPI is associated with 
AST with significant p value of < 0.05. 
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Analysis of laboratory values 
 Group N Mean Std. Deviation 
WBC Compensated 20 6045.00 1284.513 
  Decompensated 20 6220.00 1616.233 
HB Compensated 20 11.065 1.7748 
  Decompensated 20 8.565 .9713 
Platelets Compensated 20 84600.00 21724.107 
  Decompensated 20 58700.00 10367.459 
RBS Compensated 20 125.10 11.747 
  Decompensated 20 129.00 18.607 
Urea Compensated 20 30.65 4.591 
  Decompensated 20 31.15 6.620 
Creatinine Compensated 20 .980 .1240 
  Decompensated 20 .975 .1713 
proteins Compensated 20 6.50 .513 
  Decompensated 20 6.25 .444 
albumin Compensated 20 3.665 .3990 
  Decompensated 20 3.275 .3477 
AST Compensated 20 63.65 12.840 
  Decompensated 20 159.15 49.242 
ALT Compensated 20 45.60 6.793 
  Decompensated 20 110.35 30.051 
Bilirubin Compensated 20 1.118 .5056 
  Decompensated 20 7.145 1.7212 
PT Compensated 20 17.40 1.142 
  Decompensated 20 19.59 2.334 
INR Compensated 20 1.010 .1518 
  Decompensated 20 1.345 .2704 
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Table 1. Comparison of HA-PI in 2 groups 
 
HAPI COMPENSATED DECOMPENSATED P value 
Mean 1.75 1.92 < 0.001 
Standard 
deviation 
0.69 0.86 < 0.001 
 
The above table shows comparison of HA-PI between 2 groups. Normal 
HA-PI is 1.3 to 1.5. HA-PI was found to be high than normal in both groups 
indicating increased resistance due to cirrhosis, but among the 2 groups it was 
found to be higher in decompensated group (1.92). 
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Table 2.Comparison of HA-PI with CTP score 
 
HAPI CTP A CTP B CTP C P value 
Mean 1.75 
 
1.87 
 
1.96 
< 0.001 
Standard 
deviation .070 .057 
 
0.200 
 
In the above table HA-PI correlated with CTP score. It is high in those with 
CTP C indicating increased severity of liver disease. It had significant correlation 
with p value <0.001. 
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Table.3 Comparison of HA-RI in 2 groups 
HARI COMPENSATED DECOMPENSATED P value 
Mean 0.69 0.87 
< 0.001 Standard 
deviation 
0.046 0.055 
. 
The table 3 shows HA-RI higher in decompensated group (0.87). It is an 
indicator of progression of severity of liver disease. It also predicts 
decompensation of liver disease. 
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Table 4. Showing Correlation of UGI bleed with HARI and HAPI 
 UGI bleed N Mean P value 
HA RI Present 29 .8236 
<0.05 
 Absent 11 .7216 
HA PI Present 29 1.9173 
 Absent 11 1.8110 
 
Pts with UGI bleed with high HAPI and HARI had a significant p value of < 0.05. 
 Encephalopathy N Mean 
Std. 
Deviation P value 
HA RI 
Present 9 .8733 .04472 
0.039 
 
 
 
 
0.361 
Absent 31 .7513 .09612 
HA PI 
Present 9 1.9233 .18661 
Absent 31 1.8161 .11941 
 
Correlation of encephalopathy with HAPI and HARI had positive correlation but 
had no significant correlation. 
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Table 5. Comparison of HA-RI with CTP scores 
HA-RI CTP A CTP B CTP C 
MEAN 0.69 0.86 0.86 
STANDARD 
DEVIATION 
0.046 0.044 0.066 
 
The table shows comparison of CTP with HA-RI. The HA-RI increased in CTP B 
and C indicating increased progression of disease. 
 
 
 
 
 
 
   .  
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Table 6. Showing Comparison of MELD in 2 groups 
  
  
  
Group Total P value 
Compens
ated 
Decompe
nsated   
 
 
 
 
 
< 0.001 
Meld <= 10 Count 18 0 18 
    % within 
Meld 100.0% .0% 100.0% 
  > 10 Count 2 20 22 
    % within 
Meld 9.1% 90.9% 100.0% 
Total Count 20 20 40 
  % within 
Meld 50.0% 50.0% 100.0% 
 
MELD < 10 seen in 20cases and > 10 seen in 20 cases. MELD is indicator of 
severity of liver disease. We found a significant correlation with MELD in 2 
groups with p value < 0.001. 
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Table 7. Showing Mean and Standard Deviation of HARI and HAPI between 
two groups 
 Group N Mean Std. Deviation 
HA RI Compensated 
20 .6925 0.044 
 Decompensated 
20 .8650 .05511 
HA PI Compensated 
20 1.7590 .07055 
 Decompensated 
20 1.9215 .15006 
Meld Compensated 
20 9.50 .946 
 Decompensated 
20 13.80 2.016 
 
The following table shows significant association of HA-PI, HA-RI and MELD  
with p value of < 0.001. 
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Table 8. Showing Comparison of Variable/HAPI/HARI/MELD 
 
Variable COMPENSATED DECOMPENSATED P value 
HAPI 1.76 1.92 < 0.001 
HARI 0.69 0.87 < 0.001 
MELD 9.5 13.8 < 0.001 
 
HAPI and HARI higher in decompensated group as shown in above table. 
MELD is a valuable indicator of severe liver disease. HAPI is an indicator of 
resistance indicating PHT. HARI indicates progression to decompensated liver 
disease. It may be used as a noninvasive marker of progression of liver disease. 
 
All the statistical analysis was carried using the SPSS 16 software. Pearson’s 
correlation coefficient and ANOVA used for analysis of the variables. Paired‘t’ 
test was used. 
  
                                                                                              59 
 
DISCUSSION 
Doppler parameters such as Hepatic artery Pulsatile index (HAPI) and 
Resistive index (HARI) were evaluated by Schneider et al, El Kabanny et al and 
studied the correlation between HARI, HAPI and clinical features and 
complications pertaining to liver disease. Hepatic artery Resistive index (HARI) 
has also been studied to assess the tendency of liver disease to decompensate.  
 
         Liver cirrhosis is characterized by changes in portal and splanchnic 
circulation32- 38 as reported in their studies by Ohnishi et al, Sacerdoti et al 
Splanchnic vasodilation is associated with increased resistance to portal venous 
blood flow. Doppler ultrasonography has been a noninvasive method for 
evaluation of portal and renal hemodynamics. Portal vein flow has been found low 
in cirrhotics. In cirrhotics hepatic artery contributes to majority of blood flow as 
the portal venous flow is reduced in cirrhotics as reported by Schneider et al [43] 
in his studies. 
 
        Monitoring of hepatic artery indices such as Hepatic artery Pulsatile index and 
Resistive index predicts progression to decompensation and severe form of liver 
disease. Hepatic artery Pulsatile index is considered a better index of resistance and 
increased portal pressure. 
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            Hepatic arterial resistive indices (HARI) have been shown to increase in 
cirrhosis and portal hypertension. In this study it was found HAPI to be higher in 
decompensated (1.92) compared to compensated group (1.76).Higher the HAPI 
more is the resistance and portal pressure. 
       Similar findings has been reported by Schneider et al [43] who found that 
Hepatic arterial Pulsatile index (HAPI) to be higher (1.96) in cirrhotics compared 
to controls in his study and found to have direct correlation with portal pressure. 
Hepatic arterial pulsatility index (HAPI) correlated with non-invasive assessment 
of portal hypertension and it has been studied and considered as an equivalent of 
HVPG. 
In this study it was found Hepatic Resistive index to be higher in 
decompensated group (0.87) compared to compensated group (0.69) with statistical 
significance (p value < 0.001).Similar association has been reported by Rivolta et 
al [5] who found in his studies that higher the Hepatic RI (0.88) in cirrhotics, the 
more severe is the ascites and more is the severity of liver disease. 
Coli et al [21] also reported in his studies HAPI and HARI can predict 
severity of fibrosis and liver disease with a specificity of 0.95 and sensitivity of 
0.54. He also reported in his study Doppler sonography as safe and noninvasive 
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method for assessment of HAPI and HARI and correlates well with portal pressure. 
Most important disadvantage is it is highly operator dependent. 
 
        In this study a total of 40 patients of chronic liver disease were enrolled. 
There were 32 males and 8 females.  Etiology of chronic liver disease was 
evaluated. Alcohol  was found to be the commonest cause, followed by Hepatitis B 
viral infection and Autoimmune hepatitis. 
 
        The average hemoglobin was 8.5gm in decompensated group. Low 
hemoglobin in decompensated group was due to increased grade of varices, 
increased tendency for variceal bleed, anemia of chronic liver disease, poor oral 
intake, and bone marrow suppression. The platelet count was 58,700 in 
decompensated group. It may be due to PHT and hypersplenism. The AST in 
compensated was 63 IU and 159 IU in decompensated group.  In this study we 
correlated AST which is a marker of fibrosis with Hepatic arterial Pulsatile 
index(HAPI) and found significant correlation (p value < 0.05).Similar studies42 
done by  [Imber et al] have shown elevated AST, low platelet count as individual 
marker of fibrosis and cirrhosis. This forms the basis for use of these variables in 
yet another valuable score “APRI” score. 
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        In this study it was found that HAPI (1.92) and HARI (0.87) to be higher in 
decompensated group compared to compensated group. Similar association has 
been reported by El Kabanny ZA et al [44] in his studies who also found HAPI 
(1.98) and HARI (0.90) to be higher in decompensated patients especially Child C 
group.  
         In this study it was found that Hepatic artery Resistive index to be higher in 
decompensated group (0.87) compared to compensated group (0.69) and it was 
statistically highly significant with p value of < 0.001. We also found positive 
correlation between HA-PI and AST which was found to be statistically significant 
(p value <0.05). Above finding indicates the more severe is fibrosis, more is 
severity of liver disease seen in decompensated group. 
 
            Liver biopsy was carried after evaluation of coagulation profile .Since the 
study population selected for histological correlation was compensated cirrhosis, 
all patients had F4 fibrosis using Metavir fibrosis score we were unable to carry 
out histological correlation of these doppler parameters. 
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We also tried to correlate between CTP score, MELD with HAPI and HARI. 
MELD was found higher in decompensated group.In our study we found higher the 
MELD, higher is the HAPI (1.92) and HARI (0.87). Patrick Kamath et al [45] 
also reported similar findings in his studies labeling MELD as predictor of severity 
of liver disease.  
 
         Using Chi square test statistical analysis carried out between variables such 
as HAPI, HARI and MELD found to have significant p value of < 0.001.  We also 
tried to correlate platelet count with HAPI and HARI, we had positive correlation 
but found no significant correlation between them. 
 
          In this study we found HAPI (1.92) and HARI (0.87) to be higher in 
decompensated group with statistical significance (p value <0.001) indicating 
predictors of severity of liver disease. Moreover by monitoring of Hepatic artery 
Resistive index (HARI) by serial Doppler assessment we can predict which group 
of patients have tendency to decompensate, initiating aggressive management of 
portal hypertension. 
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CONCLUSION 
1. HAPI is indicator of severity of resistance due to fibrosis in both study 
groups. 
2. HAPI and HARI similar to that of MELD are non invasive doppler 
parameters predicting severity of liver disease and its progression. 
3. Hepatic artery pulsatile index had significant correlation with AST, 
indicating severe fibrosis and severe form of liver disease. 
4. All patients in compensated group had cirrhosis (F4) hence histological 
correlation could not be carried out. 
 
We need further large studies to validate the outcome of this study.  
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ABBREVIATIONS 
 
PHT- Portal Hypertension 
HA-RI    - Hepatic artery Resistive index 
HA-PI    -Hepatic artery Pulsatile index 
CTP – Child Turcotte Pugh score 
ECM- Extracellular Matrix 
ICS-Intercostal space 
HSC- Hepatic Stellate cells 
PDGF- Platelet derived growth factor 
TGF-β – Transforming growth factor 
EGF- Epidermal growth factor 
IGF- Insulin like growth factor 
HVPG- Hepatic vein pressure gradient 
SMA- Superior mesenteric artery 
AST- Aspartate aminotransferases 
USG- Ultrasound 
PV- Portal vein 
OGD- Esophagogastroduodenoscopy 
PSV- Peak systolic velocity 
PDV- Peak diastolic velocity 
Assessment of Hepatic Doppler parameters in Cirrhotics its 
clinical and Histological correlation - Proforma 
 
Name  IP no  D.O.A  
Age  + Unit  D.O.Discharge 
D.O.Death 
 
Sex  Ward  Duration of 
stay 
 
Address Diagnosis 
Phone No. 
History 
Jaundice   Altered sensorium   
Abdominal 
Distension 
  Hematemesis   
Pedal edema   Malena   
Oliguria   Weight loss   
Puffiness of face   Spontaneous 
bleeding 
  
Fever   Muscle cramps   
Anorexia   Cough   
fatigue   breathlessness   
Constipation      
Diarrhea      
Native medication      
Past h/o jaundice   Tattooing   
Diabetes   Blood transfusion   
Smoking   Drug abuse   
Alcohol 
Duration 
Gm/day 
 
 
Examination 
HE grade  Clubbing  PR  
Nutrition  Cyanosis  RR  
Height  Parotid 
swelling 
 Temp  
Weight  Gynaecomastia  BP Systolic  
BMI  Palmar 
erythema 
 Diastolic  
Anaemia  Scrotal 
swelling 
 Pulse pressure  
Icterus  Skin changes  Neck veins  
Pedal edema  Abd veins  CVS  
Ascites  Back veins  RS  
Umblical 
hernia 
 Caput medusae    
Splenomegaly  Hepatomegaly    
Investigation 
USG Abdomen 
Liver Size 
Echoes 
Ascites 
Spleen 
Endoscopy 
PV Doppler CXR 
Ascitic fluid culture 
Colour 
SAAG 
Cell count 
CTP   Urine culture  
Date      
TC      
Hb      
Platelet      
RBS      
Urea      
  
LIVER BIOPSY 
 
GRADE OF FIBROSIS 
F0 
F1 
F2 
F3 
F4 
 
 
 
 
 
Creatinine      
Sodium      
Potassium      
T.Bilirubin      
Direct      
Indirect      
SGOT      
SGPT      
ALP      
Protein      
Albumin      
globulin      
PT      
INR 
 
 
     
 LIVER PARAMETERS 
 
portal venous time-averaged 
maximum velocity 
 
HA maximum peak systolic 
velocity (HA-PSV) 
 
HA Peak diastolic velocity 
( HA-PDV) 
 
Mean velocity  
  
  
  
 
 
 
 
Hepatic artery Pulsatile index= Peak systolic velocity- Peak diastolic velocity 
                                                                     Mean velocity 
 
 
 
 
 
 
Hepatic artery Resistive index= Peak systolic velocity- Peak diastolic velocity 
                                                                 Peak systolic velocity 
 
 
 
 
 
 
 
 
      
INFORMATION SHEET 
 
                 We are conducting a study on Doppler parameters of Hepatic  
Hemodynamics in cirrhotics and to correlate them with clinical and histological 
parameters at the Department of Medical Gastroenterology, Rajiv Gandhi 
Government General Hospital, Chennai. The purpose of study is to compare 
various Doppler parameters of Hepatic and Renal Hemodynamics and correlate 
clinically, biochemically and histologically in Compensated Cirrhotics. 
         The privacy of the patient will be maintained throughout the study .In the 
event of any publication or presentation resulting from research no personal 
information will be shared. 
        Taking part in this study is voluntary. You are free to decide whether to 
participate in the study or to withdraw at anytime. Your decision will not result 
in any loss of benefits to which you are entitled. 
           The results of the study may be intimated to you at the end of the study 
period or during the study if anything is found abnormal which may aid in the 
management or treatment. 
 
 
Signature of the investigator                                         Signature of the 
participant                                                                                  
 
    
INFORMED CONSENT FORM 
 
Title of the Study: 
Doppler parameters of Hepatic Hemodynamics in Cirrhotics 
and its Clinical and Histological correlation 
Name of the Participant: 
_______________________________________  
 
Name of the Investigator: Dr. Karthikeyan .R 
 
Name of the Institution :   Madras Medical College. 
 
Documentation of the informed consent 
 
I _________________________  have read the information of this form 
(or it had been read to me). I was free to ask any questions and they 
have been answered. I hereby give my consent to be included as a 
participant  in 
Doppler parameters in Hepatic and Renal Hemodynamics in 
Cirrhotics and its Clinical and Histological correlation. 
 
1. I have read and understood this consent form and the information 
provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the 
investigator.  
 
Name and signature / thump impression of the participant 
Name _____________________ Signature _____________ Date____ 
 
Name and signature of impartial witness (required for illiterate patients): 
 
Name _____________________ Signature _____________ Date____ 
 
Address and contact number of the impartial witness: 
 
Name and signature of the investigator or his representative obtaining 
consent: 
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Group name Age in yearsSex GE No jaundice ascites UGI bleed Encephalopalcohol smoking diabetes HepatomegSplenomeg wbc hb
Compensated SANTHANAM    45 Male 6405/13 Absent Absent Present Absent Present Present Absent Absent Present 5400 14
Compensated RAJU         45 Male 196/14  Absent Absent Present Absent Present Present Absent Present Present 6700 13
Compensated VENKATESAN   50 Male 78/14   Absent Absent Present Absent Present Absent Absent Present Present 6400 10
Compensated PALANI       59 Male 6177/13 Absent Absent Absent Absent Present Present Absent Absent Present 4700 12
Compensated MUTHU        37 Male 156/14  Absent Absent Present Absent Present Present Absent Absent Present 6400 10
Compensated RAMU         44 Male 186/14  Absent Absent Present Absent Present Absent Absent Present Present 5500 12
Compensated THENARASU    48 Male 6133/13 Absent Absent Absent Absent Present Present Absent Present Absent 5400 10
Compensated RAJENDIRAN   50 Male 5455/13 Absent Absent Present Absent Present Present Absent Absent Absent 4400 10
Compensated POTHU        35 Female 5571/13 Absent Absent Present Absent Absent Absent Absent Absent Present 4500 9
Compensated SURESH       37 Male 6033/13 Absent Absent Present Absent Present Present Absent Present Absent 7700 9.5
Compensated NEELA        38 Female 6700/13 Absent Absent Absent Absent Absent Absent Absent Absent Present 6800 10
Compensated JEYARAJ      40 Male 4988/13 Absent Absent Present Absent Present Absent Absent Absent Present 4500 14
Compensated RAJALAKSHMI  43 Female 5933/13 Absent Absent Present Absent Absent Absent Absent Absent Present 6500 9.8
Compensated ANBU         48 Male 5680/13 Absent Absent Present Absent Present Present Absent Present Present 7000 11.2
Compensated NAGARAJ      49 Male 5589/13 Absent Absent Present Absent Present Present Absent Absent Present 4700 14
Compensated VEDACHALAM   50 Male 5809/13 Absent Absent Present Absent Present Absent Absent Absent Present 6800 9.6
Compensated GOVINDAN     55 Male 5890/13 Absent Absent Present Absent Present Absent Absent Present Present 5500 9
Compensated ADHILAKSHMI  60 Female 68/14   Absent Absent Absent Absent Absent Absent Absent Absent Present 7000 13
Compensated VIJAYAKUMAR  38 Male 5785/13 Absent Absent Present Absent Present Present Absent Absent Present 9500 12
Compensated VASANTHA     40 Female 6138/13 Absent Absent Present Absent Absent Absent Absent Present Present 5500 9.2
Decompensated DAMODARAN    65 Male 34/14   Present Present Present Absent Present Present Absent Present Present 6500 9
Decompensated KUPPUSAMY    34 Male 6070/13 Present Present Absent Present Present Present Absent Absent Present 5600 6.8
Decompensated DASS         35 Male 5568/13 Present Present Present Present Present Absent Absent Present Absent 6800 10
Decompensated VALIAMMAL    42 Female 5509/13 Present Present Present Present Absent Absent Absent Absent Present 7000 8.7
Decompensated ARUMUGAM     60 Male 108/14  Present Present Present Absent Present Present Absent Present Present 5400 9
Decompensated KIRUBAKARAN  63 Male 5750/13 Present Present Present Absent Present Present Absent Absent Present 5300 7
Decompensated RAJKUMAR     42 Male 4783/13 Present Present Present Absent Present Present Absent Absent Present 4300 9
Decompensated PITCHAIKARAN 42 Male 6279/13 Present Present Absent Absent Present Present Absent Absent Present 6500 7.8
Decompensated VENKATAMMAL  45 Female 6144/13 Present Present Present Absent Absent Absent Absent Absent Present 6600 9.4
Decompensated MUTHU        33 Male 6074/13 Present Present Present Absent Present Absent Absent Absent Present 7000 7.7
Decompensated Rangachari   55 Male 128/14  Present Present Absent Present Absent Absent Absent Present Present 7500 8.3
Decompensated Veeraragavan 57 Male 165/14  Present Present Present Absent Present Present Absent Absent Present 4800 7.2
Decompensated Vasanthakumar 24 Male 5919/13 Present Present Present Absent Absent Absent Absent Absent Present 4600 9.2
Decompensated Raju         60 Male 1638/14 Present Present Absent Present Present Present Absent Absent Present 5900 9.2
Decompensated Kaniyappan   69 Male 1620/14 Present Present Absent Absent Present Present Absent Absent Absent 4200 8.4
Decompensated Abdul kaboor 56 Male 1217/14 Present Present Present Present Present Absent Absent Present Present 10900 9.2
Decompensated Neelakandan  35 Male 1635/14 Present Present Present Absent Present Absent Absent Absent Present 6900 10
Decompensated Jeyakrishnan 48 Male 4657/11 Present Present Present Present Present Absent Absent Absent Absent 4400 7.4
Decompensated Raman        56 Male 1436/14 Present Present Absent Present Present Present Absent Absent Present 5600 9.6
Decompensated saroja       48 Female 486/14  Present Present Absent Present Absent Absent Absent Absent Present 8600 8.4
Group name Age in years Sex proteins albumin ast alt BILIRUBIN pt inr varices HA RI HA PI etiology meld meld_g CTP
Compensated SANTHANAM    45 Male 6 3.9 68 49 1 17 0.9 Grade I 0.70 1.70 Alcohol 8 <= 10 A
Compensated RAJU         45 Male 7 3.5 70 43 0.9 16 1 Grade II 0.70 1.87 Alcohol 8 <= 10 A
Compensated VENKATESAN   50 Male 6 3.8 68 36 1 19 1.1 Grade1 0.75 1.82 Alcohol 8 <= 10 A
Compensated PALANI       59 Male 7 3.8 57 40 1 18 1.2 No Varices 0.73 1.70 HBV     8 <= 10 A
Compensated MUTHU        37 Male 6 3.6 64 40 1.1 16 0.8 Grade I 0.74 1.80 Alcohol 9 <= 10 A
Compensated RAMU         44 Male 7 3.8 76 46 1 17 0.9 no varices 0.76 1.70 Alcohol 9 <= 10 A
Compensated THENARASU    48 Male 6 2.9 64 46 2 17 0.8 Grade I 0.70 1.80 Alcohol 9 <= 10 A
Compensated RAJENDIRAN   50 Male 7 3.6 56 39 0.9 18 0.8 Grade I 0.68 1.76 HBV     9 <= 10 A
Compensated POTHU        35 Female 7 3.5 48 45 0.8 19 1.2 GradeI 0.74 1.70 Alcohol 10 <= 10 A
Compensated SURESH       37 Male 7 4 63 47 0.9 19 1.2 GradeI 0.65 1.80 Alcohol 10 <= 10 A
Compensated NEELA        38 Female 6 4 90 64 1 17 1 GradeI 0.72 1.80 HBV     10 <= 10 A
Compensated JEYARAJ      40 Male 6 3.7 66 47 1 16 0.9 GradeI 0.62 1.64 Autoimmu 10 <= 10 A
Compensated RAJALAKSHMI  43 Female 7 4.3 72 54 1 16 0.8 GradeI 0.60 1.86 HBV     10 <= 10 A
Compensated ANBU         48 Male 7 4.4 26 36 1 17 1.1 No Varices 0.64 1.60 Alcohol 10 <= 10 A
Compensated NAGARAJ      49 Male 6 3 54 44 1 17 1.2 GradeI 0.73 1.78 Alcohol 10 <= 10 A
Compensated VEDACHALAM   50 Male 6 3.4 70 45 0.9 17 1.1 Grade I 0.62 1.76 Alcohol 10 <= 10 A
Compensated GOVINDAN     55 Male 7 4 64 46 1.1 18 0.9 Grade I 0.72 1.70 Alcohol 10 <= 10 A
Compensated ADHILAKSHMI  60 Female 6 3 66 40 0.85 19 1.1 Grade I 0.70 1.80 AUTOIMMU 10 <= 10 A
Compensated VIJAYAKUMAR  38 Male 6 3.6 55 49 0.9 16 1.2 GradeI 0.66 1.79 Alcohol 11 > 10 A
Compensated VASANTHA     40 Female 7 3.5 76 56 3 19 1 Grade II 0.69 1.80 HBV     11 > 10 A
Decompensated DAMODARAN    65 Male 7 3 160 120 6.5 18 1.2 Grade I 0.80 1.90 Alcohol 11 > 10 B
Decompensated KUPPUSAMY    34 Male 6 3.4 170 105 7 19 1.1 No Varices 0.85 1.90 Alcohol 12 > 10 B
Decompensated DASS         35 Male 7 3 220 160 12 20 1.4 Grade II 0.90 1.85 Alcohol 13 > 10 C
Decompensated VALIAMMAL    42 Female 6 3.5 165 135 9 18 1.1 Grade II 0.85 1.80 HBV     12 > 10 B
Decompensated ARUMUGAM     60 Male 6 3.7 220 145 7 17 0.8 Grade II 0.80 1.87 Alcohol 12 > 10 B
Decompensated KIRUBAKARAN  63 Male 7 4 260 150 5 18 1.3 Grade III 0.75 1.80 HBV     14 > 10 C
Decompensated RAJKUMAR     42 Male 6 3.6 140 110 4 19.5 1.4 Grade III 0.94 1.85 Alcohol 13 > 10 B
Decompensated PITCHAIKARAN 42 Male 7 3.4 76 45 5.6 18.6 1.3 GradeII 0.86 1.95 HBV     14 > 10 B
Decompensated VENKATAMMAL  45 Female 7 3.6 110 86 6 23 1.6 Grade II 0.90 1.90 HBV     15 > 10 C
Decompensated MUTHU        33 Male 6 3.5 86 65 7.6 22 1.5 GradeIII 0.86 1.86 Autoimmu 15 > 10 C
Decompensated Rangachari   55 Male 6 3 176 134 8.7 19 1 Grade II 0.85 1.90 cryptoge 11 > 10 B
Decompensated Veeraragavan 57 Male 6 2.9 156 106 9 27 2 Grade III 0.82 1.84 alcohol 19 > 10 C
Decompensated Vasanthakumar 24 Male 6 3.4 130 97 7 18 1.1 Grade III 0.85 1.85 alcohol 12 >10 C
Decompensated Raju         60 Male 6 2.9 156 90 6 21 1.3 Grade II 0.95 2.40 alcohol 14 > 10 C
Decompensated Kaniyappan   69 Male 6 3 106 88 8 18.7 1.4 Grade II 0.90 2.20 alcohol 14 <= 10 C
Decompensated Abdul kaboor 56 Male 6 3.6 92 79 7 21 1.4 GradeII 0.80 1.85 HBV     16 > 10 C
Decompensated Neelakandan  35 Male 6 2.8 170 105 8 20 1.4 GradeII 0.96 2.10 alcohol 14 > 10 C
Decompensated Jeyakrishnan 48 Male 6 3.4 200 140 6.5 18 1.5 Grade III 0.86 1.97 alcohol 15 > 10 B
Decompensated Raman        56 Male 6 3 210 137 6 18 1.3 GradeII 0.92 1.80 alcohol 13 > 10 B
Decompensated saroja       48 Female 6 2.8 180 110 7 18 1.8 Grade III 0.88 1.84 HBV     17 > 10 B
